The 2017 American Brain Tumor Association report cites that cancer is the second-leading cause of death globally, responsible for the deaths of approximately 8.8 million patients. The World Health Organization predicts the growth of cancer incidence to reach 70% in the next 20 years. Gamma knife devices face stringent market competition from other types of radiosurgery, such as linear accelerator systems (LINAC) and cyclotrons. They have meritorious features in comparison to the gamma knife in treating larger tumors in larger areas of the brain and other body parts and precisely targeting only the tumor cells, causing the least harm to the surrounding healthy cells.
Gamma knife devices are employed for cancer treatment for indications such as benign tumors, malignant tumors, functional disorders, vascular disorders, and ocular diseases. Through market estimation and data forecast, the performance of gamma knife devices as a therapy for the indication segment is elucidated.The geographical segment for gamma knife devices includes the country-level cross-sectional market estimation and data forecasting for 2015-2025.
Technological evolutions in the gamma knife devices, such as the radiation doses utilized, composite isocenters, and automated shielding for enhanced device safety and accuracy, are studied in the company profiles section. The latest mergers and acquisitions among the premier players are mentioned in recent news coverage. The competitive landscape gives information about the existing monopoly in gamma knife devices, e.g., Elekta AB, and ambitious business tactics applied by other major players to capture the market. The foremost leaders in the development of gamma knife devices for cancer treatment are Elekta AB, American Shared Hospital Services, Hokai, Cyber Medical Corporation Limited, ET Medical Group, Huiheng Medical, Inc., Masep Infini Global, Inc., Nordion, Inc., and Varian Medical Systems, Inc.
According to indications, the gamma knife devices market is classified as follows:
Benign Tumors
Malignant Tumors
Functional Disorders
Vascular Disorders
Ocular Diseases
Gamma knife is a radiation surgery therapy employed for the treatment of brain tumors, epilepsy, arteriovenous malformations, and trigeminal neuralgia. The procedure consists of delivering finely focused radiation of a high dose to the target cells, and its high degree of precision and accuracy prevents damage to the surrounding healthy cells. It is used for the treatment of abnormalities measuring 1 inch in diameter.
Malignant tumors have a big market in the indications segment as a result of the rising prevalence of patients suffering from malignant cancers. Additionally, gamma knife therapy finds huge application in the treatment of malignant tumors owing to its safety features and accuracy. Fractionated external radiation therapy is considered an adjuvant therapy for the treatment of primary brain tumors. Teletherapy, a kind of gamma knife radiosurgery, is finding huge attraction for the treatment of ocular diseases such as choroidal melanoma and uveal melanoma.
Low-radiation gamma therapy is also utilized to reduce intraocular pressure for the treatment of glaucoma. The chief players in the global gamma knife devices market are American Shared Hospital Services, Cyber Medical Corporation Limited, ET Medical Group, Elekta AB, Hokai, Huiheng Medical, Inc., Masep Infini Global, Inc., Nordion, Inc., and Varian Medical Systems, Inc.
For the purpose of this study, the global market for gamma knife devices is categorized into the following regional and country-specific markets:
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Russia
Rest of Europe
Asia-Pacific
India
China
Japan
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC Countries
South Africa
Rest of Middle East and Africa
According to the Centers for Disease Control and Prevention's 2014 survey research findings, there are approximately 1.5 million cases of invasive cancer each year, with approximately 590,000 people dying as a result of cancer. The rising prevalence of cancer and increasing demand for non-invasive radiation therapy drive the gamma knife device market in North America. Western Europe is a rapidly expanding market due to the presence of key players who pioneered the production of gamma knife devices. Additionally, the effective cancer treatment guidelines formulated by the EU have favored radiation therapy as adjuvant therapy for the treatment of cancer, which adds to the market growth in Europe. Asia Pacific dominates the gamma knife devices market on account of the rising prevalence of brain tumors and the increasing number of specialty clinics providing effective cancer diagnosis and treatment. Japan has invested heavily in the research and development of radiation therapy devices utilized for cancer treatment.
Frequently Asked Question:
The market for Gamma Knife Devices Market is expected to reach USD$ 386.6 Mn in 2025.
The Gamma Knife Devices Market is expected to see significant CAGR growth over the coming years, at 8.6 %.
The report is forecasted from 2017 -2025.
The base year of this report is 2016.
American Shared Hospital Services, Cyber Medical Corporation Limited, ET Medical Group, Elekta AB, Hokai, Huiheng Medical, Inc., Masep Infini Global, Inc. are some of the major players in the global market.
